## 4 Conclusions
Radiol._**2015**, _32_, 388-397. [CrossRef]
* [PERSON] et al. (2006) [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): Assessment of hepatic arterial embolization. _Cardiovasc. Interro. Radiol._**2006**, _29_, 522-529. [CrossRef] [PubMed]
* [PERSON] and [PERSON] (2013) [PERSON]; [PERSON] Chemoembolization and radioembolization for hepatocellular carcinoma. _Clin. Gastroenterol. Hepatol._**2013**, _11_, 604-611, quiz 6643-604. [CrossRef] [PubMed]
* [PERSON] et al. (2021) [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON] Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. _Hepatology_**2021**, _74_, 2342-2352. [CrossRef]
* [PERSON] et al. (2016) [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; et al. Y90 Radioembolization Significantly Prolonges Time to Progression Compared with Chemoembolization in Patients with Hepatocellular Carcinoma. _Gastroenterology_**2016**, _151_, 1155-1163.e1152. [CrossRef]
* [PERSON] and [PERSON] (2014) [PERSON]; [PERSON] Yttrium-90 radioembolization of liver tumors: What do the images tell us? _Cancer Imaging_**2014**, _13_, 645-657. [CrossRef]
* [PERSON] et al. (2007) [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. _AJR Am. J. Roentgenol._**2007**, _188_, 768-775. [CrossRef]
* [PERSON] et al. (2008) [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; et al. Multimodality imaging following 90Y radioembolization: A comprehensive review and pictorial essay. _Radiographics_**2008**, _28_, 81-99. [CrossRef]
* [PERSON] et al. (2023) [PERSON]; [PERSON]; [PERSON] Microwave Ablation of Recurrent Hepatocellular Carcinoma after Curative Surgical Resection. _J. Clin. Med._**2023**, _12_, 2560. [CrossRef]* [PERSON] et al. (2020) [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria. _Oncol. Lett._**2020**, _19_, 4066-4076. [CrossRef] [PubMed]
* [PERSON] et al. (2021) [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Locregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. _Nat. Rev. Gastroenterol. Hepatol._**2021**, _18_, 293-313. [CrossRef] [PubMed]
* [PERSON] et al. (2015) [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; et al. Long-Term Outcomes of Percutaneous Cryoablation for Patients with Hepatocellular Carcinoma within Milan Criteria. _PLoS ONE_**2015**, _10_, e0123065. [CrossRef] [PubMed]
* [PERSON] et al. (2021) [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON] Systematic review of the role of high intensity focused ultrasound (HIFU) in treating malignant lesions of the hepatobilinary system. _HPB_**2021**, _23_, 187-196. [CrossRef]
* [PERSON] et al. (2023) [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Irreversible electroporation of hepatocellular carcinoma and colorectal cancer liver metastases: A nationwide multicenter study with short- and long-term follow-up. _Eur. J. Surg. Oncol._**2023**, _49_, 107046. [CrossRef]
* [PERSON] et al. (2018) [PERSON] [PERSON]; [PERSON], [PERSON]; [PERSON]; [PERSON], [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON] [PERSON] Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. _BMC Gastroenterol._**2018**, _18_, 124. [CrossRef]
* [PERSON] et al.